Evolus(US:EOLS)2025-05-07 20:07Financial Performance - Total net revenues for Q1 2025 were $68.5 million, a 15.5% increase compared to Q1 2024, driven by higher volumes and market share gains[5]. - Total net revenues for Q1 2025 were $68,522,000, an increase of 15.5% compared to $59,333,000 in Q1 2024[22]. - Product revenue increased to $68,074,000 in Q1 2025, up from $58,964,000 in Q1 2024, representing a growth of 15.5%[22]. - Gross profit for Q1 2025 was $46,655,000, compared to $40,503,000 in Q1 2024, reflecting a gross profit margin of 68.1%[28]. - The net loss for Q1 2025 was $18,892,000, compared to a net loss of $13,109,000 in Q1 2024, indicating a 43.9% increase in losses[22]. - GAAP operating loss for Q1 2025 was $15.2 million, compared to $8.9 million in Q1 2024[12]. - Non-GAAP operating loss for Q1 2025 was $5.5 million, compared to $0.9 million in Q1 2024[12]. - Non-GAAP loss from operations for Q1 2025 was $5,530,000, compared to a loss of $856,000 in Q1 2024[32]. - The company reported a basic and diluted net loss per share of $0.30 for Q1 2025, compared to $0.22 in Q1 2024[22]. Membership and Market Growth - The number of accounts purchasing Jeuveau increased by 675 in Q1 2025, totaling over 16,000 accounts and achieving over 50% account penetration in the U.S.[7]. - Evolus Rewards™ membership grew by over 80,000 to over 1.1 million, representing a 39% increase compared to Q1 2024[7]. Product Launch and Future Guidance - Evolysse™ launched in April 2025 and is off to a strong start, with early metrics indicating strong interest and adoption[6]. - Evolysse™ and Estyme injectable HA gels are anticipated to contribute 8% to 10% of total revenue for the full year 2025[6]. - Full-year 2025 revenue guidance is reaffirmed at $345 million to $355 million, representing 30% to 33% growth over 2024 results[12]. - The company aims for total net revenue of at least $700 million by 2028, reflecting a compound annual growth rate of 27% from 2024[12]. Cash and Assets - Cash and cash equivalents as of March 31, 2025, were $67.9 million, down from $87.0 million on December 31, 2024[12]. - Cash and cash equivalents decreased to $67,894,000 as of March 31, 2025, down from $86,952,000 at the end of 2024[24]. - Total assets decreased to $213,361,000 as of March 31, 2025, compared to $232,569,000 at the end of 2024[24]. - Total stockholders' equity (deficit) was $(6,604,000) as of March 31, 2025, down from $5,522,000 at the end of 2024[24]. Operating Expenses - Operating expenses rose to $61,827,000 in Q1 2025, up from $49,425,000 in Q1 2024, marking a 25.1% increase[30].